Pragma Bio (former VastBiome)
Mining the molecules that matter.
San Francisco, United States · Founded 2019 · $14.5M raised
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2019
- Website
- vastbiome.com
- Total Funding
- $14.5M
- Last Round
- $10.0M Series AMar 2023
- Rounds
- 2
About
Pragma Bio (formerly VastBiome) is a biotechnology company discovering new medicines using a biology-first, AI-enabled approach that mines gut-derived small molecules for therapeutic potential. The company's proprietary PIKASO platform uses bioinformatics and AI to identify Biosynthetic Gene Clusters (BGCs) from the gut microbiome, then applies synthetic biology and medicinal chemistry to make and test novel small molecules targeting the gut-immune axis. Pragma Bio focuses on immunological disorders and applies phenotypic screening to uncover new disease-modifying pathways and de-risk efficacy early in development.
Summary
Pragma Bio (former VastBiome) is a Healthcare company based in San Francisco, United States, founded in 2019. It has raised $14.5M in total across 2 rounds, most recently a $10.0M Series A round in Mar 2023.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2023
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company